CD19 and neoplasm: The cytotoxicity of CAR19-iNK-like cells was tested against CD19-positive target tumor cells, including human acute lymphoblastic leukemia (ALL)-derived REH cells and human Burkitt’s lymphoma (BL)-derived Raji cells.